Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GNLX

Genelux

GNLX Lead: Phase 3 2 Biotech Distilled articles ↓ 10 filings & releases ↓ Cash $9.2M (Jun 30, 2026) ↓ 2 verdicts ↓
Oncology Gene Therapy

Market cap $88.7M 45.2M shares (10-Q, Aug 11, 2026) × $1.96 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Olvi-Vec NSCLC Ph2 interim2026Olvi-Vec NSCLC Ph2 interim, 2026, notable
  2. Olvi-Vec SCLC Ph2 interim2026Olvi-Vec SCLC Ph2 interim, 2026, notable
  3. Olvi-Vec OnPrime Ph3 topline2H 2026Olvi-Vec OnPrime Ph3 topline, 2H 2026, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (3 active programs)

Technology platforms

CHOICE

Proprietary selection technology and discovery/development platform based on a collection of vaccinia virus (VACV) strains selected on multiple in vitro and in vivo criteria; generates oncolytic VACV immunotherapy candidates for multiple solid tumor types in monotherapy and combination settings

Capital (as filed)

Cash
$9.2M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$9.5M Jun 30, 2026
Operating cash flow
−$6.4M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$18.7M cash, runway the first quarter of 2027 per the update of Aug 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Genelux, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-15 Watch Genelux Corporation (GNLX) — Scientific Deep Dive for Olvi-Vec and Pipeline Products The science is legitimate and the randomized pivotal genuinely de-risks the single-arm knock, but with runway ending at the 2H-2026 readout, a going-concern warning, certain dilution, and a modality that has never commercialized, this is a binary event trade to watch, not own.
  2. 2026-08-14 Watch UPDATE: Genelux (GNLX) - The Fuel Gauge Meets the Catalyst Q2 burn accelerated to $9.6M against $18.7M total cash with the Phase 3 topline still guided to 2H 2026, tightening the runway squeeze but leaving the scientific thesis and watch-list stance unchanged.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (10)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 13, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)